Peptide Drug R&D Frontier Session – Agenda Release
Jun 05,2026
Peptide drugs stand at the threshold of a major transition — from blockbuster products to an industry-wide wave. The multi-billion dollar success of GLP-1 has opened the imagination for peptide therapeutics. The next-generation opportunities are extending into broader horizons: multi‑targeting, oral delivery, AI‑driven discovery, cyclic peptides, and beyond. A hundred‑billion‑dollar blue ocean is now on the horizon. Who will define the next decade?
"Peptide Drug R&D Frontier – From the Hundred‑Billion Blue Ocean to Innovation Leap" — the full agenda is released today. This session brings together leading scientists and industry pioneers from across the peptide field to deeply explore the technological leap and industrial pathways within this hundred‑billion‑dollar arena. Discussions will cover key frontiers including GLP‑1 R&D insights, cyclic peptide discovery driven by AI and mRNA display, breakthroughs in oral peptide delivery, and the development of multi‑target agonists — as well as the opportunities and challenges for China's peptide innovation to go global.
July 22–24, Shanghai National Exhibition and Convention Center — we look forward to exploring the future frontiers of peptide therapeutics with you.
Agenda
Session Co‑organizer: Revvity
GLP‑1 R&D Journey and Outlook
Wang Qinghua: Founder, Chairman & CEO, Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Cyclic Peptide Discovery Integrating mRNA Display and AI
Cui Haifeng: CSO, Shanghai Highline Therapeutics, Inc.
CMC for Peptide Drugs
WuXi AppTec Co., Ltd.
AI‑Designed Cyclic Peptide Drugs to Tackle Undruggable Targets
Zhang Genwei: Peptide R&D Lead, XtalPi Holdings Limited
TBD
Wu Fangzhou: Head of Peptide Biology Department, Hengrui Medicine | Tuojie Biomedical (Invited)
Peptide Drug Screening and Evaluation – From GLP‑1 to Multi‑Target Agonists
Wang Xinyuan: Technical Manager, Application Business, Revvity China
Panel Discussion:
- Beyond GLP‑1 – Where is the next hundred‑billion‑dollar opportunity for peptide drugs?
- How can China's innovative drug industry define the value of the peptide industry chain?
- China's peptide innovation going global – Opportunities, challenges, and future directions?
Liu Jiang (Moderator): Global Vice President & General Manager, Greater China, Revvity
Panelists:
Cao Chunlai: CEO, Federal Biotechnology (Zhuhai Hengqin)
Chen Xiaoxin: Vice President, Guangdong Zhongsheng Pharmaceutical ; Co‑Founder, Chairman & CEO, Guangdong Zhongsheng Ruichuang Biological Technology
Huang Baohua: Founder & CEO, Coherent Biopharma
Zhai Peng: Co‑Founder, Senior Vice President & Head of CMC and Manufacturing, QL Biopharm
Zhang Yingjun: Chairman, Sunshine Lake Pharma
Follow or Contact Us
Follow the TONACEA Official WeChat Account and scan the QR code to register. Stay updated with the latest conference news.
Public Account QR Code
Registration QR Code
Conference Service Hotline
© 2026 TONACEA (Shanghai) Technology Development Co., Ltd. All rights reserved. All rights reserved.
